REG - Adv Medical Solutns. - Total Voting Rights

Advanced Medical SolutionsAnnouncement

28/03/2024 17:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240328:nRSb7973Ia&default-theme=true

RNS Number : 7973I  Advanced Medical Solutions Grp PLC  28 March 2024

 

28 March 2024

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Total Voting Rights

 

In accordance with Disclosure and Transparency Rule 5.6.1, the issued share
capital of Advanced Medical Solutions Group plc as at 28 March 2024 comprises
217,341,362 ordinary shares of 5p each with voting rights. There are no shares
held in treasury.

 

The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules.

 

-     Ends -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Consilium                                    Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone            AMS@consilium-comms.com

 Investec Bank plc (NOMAD and Broker)             Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 HSBC Bank plc (Broker)                           Tel: 44 (0) 20 7991 8888

 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made five acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products, AFS Medical, an Austrian a specialist surgical
business with a focus on minimally invasive procedures, and Connexicon
Medical, an Irish tissue adhesives specialist.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group
has R&D innovation hubs in the UK, Germany, France, Ireland and Israel.
Established in 1991, the Group has more than 900 employees. For more
information, please see www.admedsol.com (http://www.admedsol.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAXDPAEALEFA